

PATENT COOPERATION TREATY

From the
INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY

PCT

To:

JÖNSSON, Hans-Peter
Von Kreisler Selting Werner
Deichmannhaus am Dom
Bahnhofsvorplatz 1
50667 Cologne
ALLEMAGNE

Av	K	Sg	W	Da	Hi	HP	ME	TW	JH	KB
12. SEP. 2005										
CS	K	F3.1.06m								

NOTIFICATION OF TRANSMITTAL OF
THE INTERNATIONAL PRELIMINARY
REPORT ON PATENTABILITY

(PCT Rule 71.1)

Date of mailing
(day/month/year)

09.09.2005

Applicant's or agent's file reference
041748wo HPJ

IMPORTANT NOTIFICATION

International application No.
PCT/EP2004/007215

International filing date (day/month/year)
02.07.2004

Priority date (day/month/year)
03.07.2003

Applicant
B. BRAUN MEDICAL AG et al.

1. The applicant is hereby notified that this International Preliminary Examining Authority transmits herewith the international preliminary report on patentability and its annexes, if any, established on the international application.
2. A copy of the report and its annexes, if any, is being transmitted to the International Bureau for communication to all the elected Offices.
3. Where required by any of the elected Offices, the International Bureau will prepare an English translation of the report (but not of any annexes) and will transmit such translation to those Offices.

4. REMINDER

The applicant must enter the national phase before each elected Office by performing certain acts (filing translations and paying national fees) within 30 months from the priority date (or later in some Offices) (Article 39(1)) (see also the reminder sent by the International Bureau with Form PCT/IB/301).

Where a translation of the international application must be furnished to an elected Office, that translation must contain a translation of any annexes to the international preliminary report on patentability. It is the applicant's responsibility to prepare and furnish such translation directly to each elected Office concerned.

For further details on the applicable time limits and requirements of the elected Offices, see Volume II of the PCT Applicant's Guide.

The applicant's attention is drawn to Article 33(5), which provides that the criteria of novelty, inventive step and industrial applicability described in Article 33(2) to (4) merely serve the purposes of international preliminary examination and that "any Contracting State may apply additional or different criteria for the purposes of deciding whether, in that State, the claimed inventions is patentable or not" (see also Article 27(5)). Such additional criteria may relate, for example, to exemptions from patentability, requirements for enabling disclosure, clarity and support for the claims.

Name and mailing address of the international
preliminary examining authority:



European Patent Office
D-80298 Munich
Tel. +49 89 2399 - 0 Tx: 523656 epmu d
Fax: +49 89 2399 - 4465

Authorized Officer

Jacobus Prues, S
Tel. +49 89 2399-8113



BEST AVAILABLE COPY


PATENT COOPERATION TREATY

PCT

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

(Chapter II of the Patent Cooperation Treaty)

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference 041748wo HPJ	FOR FURTHER ACTION		See Form PCT/PEA/416
International application No. PCT/EP2004/007215	International filing date (day/month/year) 02.07.2004	Priority date (day/month/year) 03.07.2003	
International Patent Classification (IPC) or national classification and IPC B32B27/08, B32B27/30, B32B27/32, B32B27/36, A61J1/00			
Applicant B. BRAUN MEDICAL AG et al.			
<p>1. This report is the international preliminary examination report, established by this International Preliminary Examining Authority under Article 35 and transmitted to the applicant according to Article 36.</p> <p>2. This REPORT consists of a total of 5 sheets, including this cover sheet.</p> <p>3. This report is also accompanied by ANNEXES, comprising:</p> <p style="margin-left: 20px;">a. <input checked="" type="checkbox"/> sent to the applicant and to the International Bureau) a total of 3 sheets, as follows:</p> <p style="margin-left: 40px;"><input checked="" type="checkbox"/> sheets of the description, claims and/or drawings which have been amended and are the basis of this report and/or sheets containing rectifications authorized by this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions).</p> <p style="margin-left: 40px;"><input type="checkbox"/> sheets which supersede earlier sheets, but which this Authority considers contain an amendment that goes beyond the disclosure in the international application as filed, as indicated in item 4 of Box No. I and the Supplemental Box.</p> <p style="margin-left: 20px;">b. <input type="checkbox"/> (sent to the International Bureau only) a total of (indicate type and number of electronic carrier(s)) , containing a sequence listing and/or tables related thereto, in computer readable form only, as indicated in the Supplemental Box Relating to Sequence Listing (see Section 802 of the Administrative Instructions).</p>			
<p>4. This report contains indications relating to the following items:</p> <p><input checked="" type="checkbox"/> Box No. I Basis of the opinion</p> <p><input type="checkbox"/> Box No. II Priority</p> <p><input type="checkbox"/> Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability</p> <p><input type="checkbox"/> Box No. IV Lack of unity of invention</p> <p><input checked="" type="checkbox"/> Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement</p> <p><input type="checkbox"/> Box No. VI Certain documents cited</p> <p><input type="checkbox"/> Box No. VII Certain defects in the international application</p> <p><input type="checkbox"/> Box No. VIII Certain observations on the international application</p>			
Date of submission of the demand 03.05.2005		Date of completion of this report 09.09.2005	
Name and mailing address of the international preliminary examining authority:  European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465		Authorized Officer Seiberlich, P Telephone No. +49 89 2399-8663	



INTERNATIONAL PRELIMINARY REPORT
ON PATENTABILITYInternational application No.
PCT/EP2004/007215

IAP5 Rec'd PCT/PTO 22 DEC 2005

Box No. I Basis of the report

1. With regard to the **language**, this report is based on the international application in the language in which it was filed, unless otherwise indicated under this item.
- ☐ This report is based on translations from the original language into the following language, which is the language of a translation furnished for the purposes of:
- ☐ international search (under Rules 12.3 and 23.1(b))
 - ☐ publication of the international application (under Rule 12.4)
 - ☐ international preliminary examination (under Rules 55.2 and/or 55.3)
2. With regard to the **elements*** of the international application, this report is based on *(replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report)*:

Description, Pages

1-20 as originally filed

Claims, Numbers

1-15 received on 23.08.2005 with letter of 22.08.2005

Drawings, Sheets

1/4-4/4 as originally filed

- ☐ a sequence listing and/or any related table(s) - see Supplemental Box Relating to Sequence Listing
3. ☐ The amendments have resulted in the cancellation of:
- ☐ the description, pages
 - ☐ the claims, Nos.
 - ☐ the drawings, sheets/figs
 - ☐ the sequence listing *(specify)*:
 - ☐ any table(s) related to sequence listing *(specify)*:
4. ☐ This report has been established as if (some of) the amendments annexed to this report and listed below had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).
- ☐ the description, pages
 - ☐ the claims, Nos.
 - ☐ the drawings, sheets/figs
 - ☐ the sequence listing *(specify)*:
 - ☐ any table(s) related to sequence listing *(specify)*:

* If item 4 applies, some or all of these sheets may be marked "superseded."

**INTERNATIONAL PRELIMINARY REPORT
ON PATENTABILITY**

International application No.
PCT/EP2004/007215

Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)	Yes: Claims	1-15
	No: Claims	
Inventive step (IS)	Yes: Claims	1-15
	No: Claims	
Industrial applicability (IA)	Yes: Claims	1-15
	No: Claims	

2. Citations and explanations (Rule 70.7):

see separate sheet

Re Item V

**Reasoned statement with regard to novelty, inventive step or industrial applicability;
citations and explanations supporting such statement**

The following document/s (D) is/are referred to in this communication:

D1: EP-A-0 774 348 (BRAUN MELSUNGEN AG)

1. Novelty

Document D1, which is considered to represent the most relevant state of the art, discloses sterilisable co-extruded films for wrapping containers for solutions, suspensions, solids or mixtures for parenteral, enteral or stomach tube feeding.

The tube consists of three layers, i.e.

- (a) polypropylene homopolymer (homo-PP, outer layer),
- (b) ethylene vinylalcohol copolymer (EVOH), in particular a copolymer with an ethylene content of 27-38 mole% and
- (c) a single-phase PP homo- or co-polymer (inner layer).

The three layers (a), (b) and (c) have thicknesses of 20-40 μm (a), 15-35 μm (b) and 30-50 μm , respectively; cf. D1, the passages cited in the Search Report, in particular the claims. The material of inner layer (b) is selected to provide the required oxygen barrier properties. It is clear that the ethylene content of the EVOH copolymer is selected to maintain barrier properties during sterilization at 121°C (cf. p 2/3, bridging paragraph and p 3/1 11-21 and 37).

The claimed films differ from those according to D1 in the nature of the outer layer (i.e. the presence of a (co)PET outer layer. Thus, the claimed films are novel over the disclosure in D1. The subject-matter of present claims 1-15 therefore appears to meet the requirements of Article 33(2) PCT.

2. Inventive Step

The claimed films differ from the most relevant state of the art (D1) in the nature of their

outer layer and in their desorption properties.

The problem to be solved by the present application may therefore be regarded as to provide multilayer films having a low oxygen transmission rate (i.e. $<0.7 \text{ ml/m}^2\text{d}$) and at the same time allowing for improved recovery of the gas barrier properties of the core layer after sterilization.

It appears from a comparison of the results presented in Fig. 3 that the presence of an outer layer of PET instead of PP renders the obtainable films more effective in the desorption of water and, thus, improves the long term barrier properties of the corresponding container.

None of the documents of the prior art contains an incentive for the skilled person to combine layers of a saponified polyolefin-vinyl acetate copolymer in combination with layers of a polyalkylene terephthalate resin (e.g. bonded by means of an adhesive) when aiming at structures allowing for improved desorption of water e.g. absorbed during sterilization. Thus, the subject-matter of present claims 1, 12 and 13 appears to meet the requirements of Article 33(3) PCT.

Claims 2-11, 14 and 15 are dependent on claim 1 or 13 and as such also meet the requirements of the PCT with respect to novelty and inventive step.

PCT/EP2004/007215

HPJ/RC/cr

3 May 2005

B. Braun Medical AG

Amended Claims:

1. Sterilizable multilayer film for containers containing solutions, suspensions, solids or mixtures for parenteral or enteral nutrition or tube feeding, optionally in a spatially separated arrangement of the contents, having a three-layered structure with an inner layer being in contact with the content of the container, an intermediate layer and an outer layer facing the environment, said layers optionally connected by tie and/or adhesive layers, wherein the oxygen transmission rate at 23 °C through the multilayer film determined by the oxygen transmission of the intermediate layer is less than 0.7 ml/m²d, said inner layer having a thickness of from 30 to 120 µm, said intermediate layer having a thickness of from 5 to 35 µm and said outer layer having a thickness of from 20 to 40 µm, and **comprising or substantially consisting of polyethylene terephthalate homopolymer and/or polyethylene terephthalate copolymer**, and allowing desorption of water absorbed in the intermediate layer during sterilization after said sterilization at 121 °C.
2. The multilayer film according to claim 1, wherein said oxygen transmission rate at 23 °C is less than 0.4 ml/m²d.
3. The multilayer film according to claim 1 or 2, having an inner layer essentially consisting of non-polar polymeric material.
4. The multilayer film according to claim 3, having an inner layer comprising or substantially consisting of polypropylene homopolymer and/or polypropylene copolymer.

5. The multilayer film according to any one of claims 1 to 4, having an intermediate layer comprising or substantially consisting of ethylene/vinyl alcohol copolymer, having a defined ethylene content of 27 to 38, in particular 29 to 32 mol-%.
6. The multilayer film according to any one of claims 1 to 5, characterized in that the multilayer film contains at least one oxygen absorber within one or several of the layers.
7. The multilayer film according to claim 6, wherein said oxygen absorber contains or consists of Fe or Fe(II)-salts.
8. The multilayer film according to claim 6 or 7, wherein said oxygen absorber is contained in said inner layer.
9. The multilayer film according to any one of claims 6 to 8, wherein said oxygen absorber is contained in a tie and/or adhesive layer located between said inner layer and said intermediate layer.
10. The multilayer film according to any one of claims 6 to 9, wherein said oxygen absorber is contained in the respective layer/layers in an amount of 1 to 100 mg/g, particularly 5 to 20 mg/g related to the weight of the respective layer.
11. The multilayer film according to anyone of claims 6 to 10, wherein said oxygen absorber is contained in an amount of 0.5 to 2.0 mg/g related to the overall weight of all layers.
12. Vapor sterilized multilayer film according to any one of claims 1 to 11.

13. Use of the multilayer film according to any one of claims 1 to 12 as a pharma film.

14. Use according to claim 13 to preserve the quality of products for infusion, PVR, dialysis, urology and/or clinical nutrition.

15. Use according to claim 13 or 14 to minimize oxidation and/or adsorption of the ingredients of said products.

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☒ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.